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Abstract
Background:  Single nucleotide polymorphisms (SNPs) in the dhfr and dhps genes are associated with sulphadoxine- 
pyrimethamine (SP) treatment failure and gametocyte carriage. This may result in enhanced transmission of mutant malaria 
parasites, as previously shown for chloroquine resistant parasites. In the present study, we determine the association 
between parasite mutations, submicroscopic P. falciparum gametocytemia and malaria transmission to mosquitoes.
M eth od olog y/P rin cipa l Fin d in g s: Samples from children treated with SP alone or in combination with artesunate (AS) or 
amodiaquine were genotyped for SNPs in the dhfr and dhps genes. Gametocytemia was determined by microscopy and 
Pfs25 RNA-based quantitative nucleic acid sequence-based amplification (Pfs25 QT-NASBA). Transmission was determined 
by membrane-feeding assays. We observed no wild type infections, 66.5% (127/ 191) of the infections expressed mutations 
at all three dhfr codons prior to treatment. The presence of all three mutations was not related to higher Pfs25 QT-NASBA 
gametocyte prevalence or density during follow-up, compared to double mutant infections. The proportion of infected 
mosquitoes or oocyst burden was also not related to the number of mutations. Addition of AS to SP reduced 
gametocytemia and malaria transmission during follow-up.
C on clusion s/S ignifican ce: In our study population where all infections had at least a double mutation in the dhfr gene, 
additional mutations were not related to increased submicroscopic gametocytemia or enhanced malaria transmission. The 
absence of wild-type infections is likely to have reduced our power to detect differences. Our data further support the use of 
ACT to reduce the transmission of drug-resistant malaria parasites.
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Introduction
Artemisinin-based com bination therapy (ACT) is now widely 
advocated as first-line antim alarial treatm ent. Nevertheless, drugs 
that are now no longer recom m ended as first-line treatm ent, such as 
sulphadoxine-pyrim etham ine (SP), will continue to play a  role in 
m alaria control. A change in international therapeutic recom m en­
dations is no t always translated into an  imm ediate, effective policy 
change a t country levels. In  K enya, m onotherapy with chloroquine 
was replaced by SP in 1998 and SP was officially replaced by the 
A C T  A rtem ether-Lum efantrine (AL) in 2004 [1]. However, health 
worker training and  distribution of AL were not com pleted until the 
end o f 2006 [1]. Even if official recom m endations are followed by 
governm ent services, m onotherapy will rem ain available in the 
private sector, as was reported  in Nigeria [2]. Furtherm ore, SP also
plays an  im portant role in interm ittent preventive treatm ent to 
control m alaria in infants [3,4] and  pregnant wom en [5] and  in some 
situations the com bination of SP with am odiaquine (AQ) m ay be a 
cheap and  efficacious alternative to A C T  [6,7]. T he ongoing use of 
SP, either in treatm ent of uncom plicated m alaria o r as m ethod of 
m alaria control by  interm ittent preventive treatm ent, underlines the 
im portance of continued studies of SP resistance and  the way 
resistance spreads in populations.
SP resistance is associated w ith the presence of single nucleotide 
polym orphism s (SNPs) in the dhfr an d  dhps genes [8-10]. This SP 
resistance starts off w ith a  core SN P a t codon 108 (S108N), which 
is followed by m utations a t c51 (N51I) an d  59 (C59R) [11] leading 
to a  so-called ‘triple m uta tion ’. A dditional m utations in the dhps 
gene (codon 437 and  540) are related with even h igher risks for SP 
trea tm en t failure [12]. O th e r codons (in dhfr a t c164 and  dhps at
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c581 an d  c613) are also associated w ith high-level SP resistance in 
Southeast Asia [13,14] an d  L atin  A m erica [9], b u t until now, these 
m utations are uncom m on on the African continent an d  have 
rarely been found in East Africa [15-19].
T h e  presence o f m utations in the dhfr an d  dhps genes m ay not 
only predic t trea tm en t outcom e, b u t m ay also be related to the 
transm ission stages o f  P. falciparum, the gametocytes. T h e  presence 
o f resistant parasites a t enro lm ent was found to be related  to 
m icroscopically detected gametocytes during  follow-up [20,21] or 
even prio r to trea tm en t [21] and  to the duration  o f gam etocyte 
carriage [22]. M utations in the Pfcrt and  Pfmdr1 genes, encoding 
C Q  resistance, were associated with a  higher gam etocyte density 
and  subsequent m alaria  transm ission after C Q  m onotherapy 
[23,24] o r S P /C Q c o m b in a tio n  trea tm en t [25]. Recently, a  study 
o f M endez and  others showed th a t in C olom bia, m alaria  
transm ission was enhanced  for parasites w ith low levels o f 
resistance to SP com pared  to fully sensitive parasites [26]. In 
addition to a  transm ission advantage o f m utan t parasites in the 
hu m an  host th rough  a  h igher gam etocyte prevalence or density 
[20,23], there  m ay also be a  selective advantage in the m osquito 
m idgut, as was suggested for Pfcrt m utations [23]. T hese findings 
are worrying, indicating a very rap id  spread of m utan t parasites 
under d rug  pressure, b u t need confirm ation in areas with different 
levels o f transm ission intensity and  d ru g  resistance.
M olecular gam etocyte detection tools have recently dem on­
strated th a t gam etocyte carriage can be  seriously underestim ated  
by the use o f m icroscopy [27]. Subm icroscopic gametocytes are 
no t only com m on in various populations [27-29], b u t m ay also 
contribute considerably to m alaria  transm ission [27].
T h e  present study was conducted  in an  area  o f high resistance to 
SP with m ore th an  50% trea tm en t failure w ithin one m onth  of 
follow-up [27]. Samples from  a previously published study on 
subm icroscopic gam etocytem ia following antim alarial treatm ent 
[27] were genotyped to determ ine the relation betw een parasite 
m utations, subm icroscopic gam etocytem ia and  the transm ission of 
m alaria  to m osquitoes.
M ethods
Ethics statement
T h e  study protocol (SSC No. 791) was approved by the Scientific 
Steering Com m ittee and Ethical Review Com m ittee o f the K enya 
M edical Research Institute. W ritten, inform ed consent was obtained 
from a paren t o r guardian o f the participating children. T he trial was 
com pleted in  2004, before registration becam e m andatory for 
clinical trials. T h e  trial was registered after completion under 
Clinical Trials registration num ber ISR C T N 31291803 (h ttp ://  
ww w .controlled-trials.com /ISR C TN 31291803).
Objectives
W e hypothesized that m utan t parasites possess a  transmission 
advantage com pared to susceptible parasites. T o  test this hypothesis, 
our prim ary objectives were to determ ine the num ber o f allelic 
variants before and after treatm ent and  to determ ine the relation 
betw een m utations in the dhfr and  dhps genes and: i) gametocyte 
prevalence and  density by m icroscopy and  R N A -based quantitative 
nucleic acid sequence based amplification (QT-NASBA); ii) 
m osquito infection rates; iii) oocyst densities in mosquitoes.
Participants
This study was conducted  from  O ctober to D ecem ber 2004 
(short ra iny  season) in M bita, a  ru ral village on  the shores o f Lake 
V ictoria in Suba District, western K enya. T h e  m ain  m alaria  
vectors in the area  are A. gambiae, A. funestus, and  A. arabiensis.
M alaria transm ission is high and  perennial, w ith parasite 
prevalences in the hu m an  population  ranging from  24.4%  to 
99.0% . Generally, the rainfall p a tte rn  is bim odal, w ith a  long rainy 
season betw een M arch  and  M ay an d  a  short rainy  season betw een 
O ctober and  D ecem ber.
T he study population and  treatm ent procedures are described 
elsewhere [27]. Briefly, 528 children (6 m onths-10 years) with P. 
falciparum m ono-infection with a  m inim um  parasite density o f 5 0 0 / 
parasites mL, fever or history o f fever in the last 48 hours and  absence 
o f danger signs were enrolled and  random ised to treatm ent with 
sulphadoxine-pyrim etham ine (SP; Fansidar®, Roche, Switzerland), 
SP plus am odiaquine (AQ; Camoquine®, Pfizer, Senegal), SP + 
Artesunate (AS; Arsumax®, Sanofi, France) or Artem ether-Lum e- 
fantrine (AL; CoArtem®, Novartis Pharm a, Switzerland). Samples 
were random ly selected from  the study populations o f 2003 and 2004 
for m olecular analysis o f gametocyte carriage [27]. In  addition, a 
random  selection of 25 children pe r treatm ent arm  was invited for 
m em brane feeding experiments and  m olecular analysis o f gam eto­
cyte carriage, irrespective o f gametocyte carriage status [27]. 
Samples from these two groups were com bined and  used for 
parasite genotyping in the current study. O nly children who received 
SP alone o r in com bination with AQ or AS were included in the 
curren t study because we were interested in the transmission 
potential in relation to m utations in the dhfr and  dhps genes (i.e. 
m utations that are associated with SP treatm ent failure). In  addition, 
we determ ined the prevalence ofm utations in the Pfcrt gene that are 
associated with A Q  treatm ent failure.
Description of procedures
M icro sco p y  and  P fs25 QT-NASBA. Blood smears were 
stained w ith 10% Giem sa for 10 m in an d  then screened for 
asexual parasites and  gametocytes a t enro lm ent and  on  days 3, 7, 
14, an d  28. Asexual parasites an d  gametocytes were counted 
against 200 an d  500 white blood cells (WBCs), respectively, and  
the counts were converted to parasites pe r m icroliter on  the 
assum ption o f a  density o f 8000 W BCs/m L. Parasite detection by 
Pfs25 Q T-N A SB A  was done a t day 0, 3, 7, 14 an d  28 as described 
elsewhere [30,31], using a NucliSens E asy Q  analyser (bioMerieux) 
as described elsewhere for Pfs25 m R N A  [30]. Nucleic acids were 
extracted from  50-mL blood samples as described by Boom  and  
others [32]. T h e  Pfs25 Q T-N A SB A  technique is gam etocyte 
specific and  has a  detection lim it o f  0.02-0.1 gam etocytes/m L. 
NucliSens Basic kits w ere used for amplification, in accordance 
with the m anufacturer’s instructions. A standard  dilution series o f 
m ature, in v itro -cu ltu red  N F54 gametocytes [33] was included in 
each run  to determ ine gam etocyte densities in the test samples.
M o sq u ito  m em b ra n e  feed in g  and  d issec tio n . M em brane­
feeding assays were conducted  on day 14 after treatm ent, as 
described elsewhere [27]. Briefly, 3-m L venous b lood samples 
were obtained and  fed to —150 locally reared  [34] 4-5-day-old  
female A. gambiae sensu stricto m osquitoes via an  artificial 
m em brane a ttached  to a  w ater-jacketed glass feeder m aintained 
a t 37°C. After 10-15 m inutes, fully fed m osquitoes were selected 
and  kept on  glucose for 7 days a t 27°C -29°C , a t w hich time 
m idguts were dissected in 2% m ercurochrom e. M idguts were 
exam ined m icroscopically for oocysts, w ith a  second m icroscopist 
confirm ing their presence if observed. Exactly 30 m osquitoes were 
dissected p e r child.
D e tec tio n  o f  SN Ps in  d h fr /d h p s  and  P fcrt by PCR and  
SSOP-ELISA. Sam ples collected a t p a tien t enrolm ent were 
screened for SNPs a t dhfr c108, c59 and  c51, using P C R -S SO P 
as previously described [25,35] an d  provided an  estim ate o f 
baseline allele frequencies a t this locus. Samples from  individuals 
participating  in m em brane feeding experim ents were m ore
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extensively studied for SNPs in both the dhfr and dhps genes. For 
these samples, SNPs at dhfr (at c50/51, c59, c108 and c164), dhps 
(at c436/437, c540, c581 and c613) and Pfcrt (position 72-76) were 
determined by SSOP-ELISA of PCR amplified fragments using 
conditions and reagents as described by Alifrangis and others [36]. 
For each SNP analyses, parasite samples were categorized into 
single, mixed but with one SNP in majority or mixed infections with 
no SNP in majority as described by Alifrangis and others [36]. The 
mixed samples with one SNP in majority were considered as single 
mutations. All SSOP-ELISA data were divided into wild or mutant 
type; samples with a mixed infection (wild-type and mutant) were 
considered as mutant. Samples with a mutation in c108+c59 or 
c108+c51 of dhfr but no additional mutations were classified as 
double mutations; samples with mutations in c51+c59+c108 as triple 
mutations; samples with mutations in c51+c59+c108 of dhfr and c437 
of dhps were considered quadruple mutations; and samples with 
mutations in c51+c59+c108 of dhfr and c437+c540 of dhps as 
quintuple mutations. For confirmation of the rare c164L genotype in 
dhfr the PCR-restriction fragment length polymorphism (RFLP) 
method described by Duraisingh and others [37] was used.
Statistical methods and sample size considerations
The major objective of the current study was to determine post­
treatm ent malaria transmission potential in relation to mutations 
in the dhfr and dhps genes. This objective was studied using samples 
from a previously published drug efficacy trial [27] where the 
sample size for transmission experiments was based on the 
comparison of transmission potential after SP monotherapy 
compared to ACT. In the absence of information on the 
prevalence of mutations in the dhfr and dhps genes in the study 
area or their expected association with submicroscopic gameto- 
cytes and malaria transmission, we based sample size consider­
ations for the current study on previously published studies on the 
relation between mutations in the Pfcrt gene and malaria 
transmission. Three previously conducted studies included 11-25 
membrane-feeding experiments per treatm ent arm with an 
average of 20-30 mosquitoes per experiment [23-25]. We 
included samples from 75 membrane-feeding experiments in 
randomly selected individuals after SP (n = 25), SP+A Q(n = 25) or 
SP+AS treatm ent (n = 25). Thirty mosquitoes were examined per 
experiment, giving a total of 2250 mosquitoes [27,38]. Because 
post-treatment gametocytemia and malaria transmission was 
previously shown to be similar for SP and SP+A Q  [27], data 
was grouped as non-ACT (SP mono-therapy and SP+A Q  
combination therapy) or A CT (SP+AS) for analyses on the 
relation between m utant genotypes and post-treatment gameto- 
cytemia and malaria transmission. The transmission potential 
during follow-up was quantified as the area under the curve of 
Pfs25 QT-NASBA gametocyte density versus time (AUC). This 
measure incorporates both the magnitude and the duration of 
gametocyte carriage and was described by Mendez and others 
[39]. Mosquito transmission experiments were analyzed based on 
the proportion of infectious children, the proportion of infected 
mosquitoes and oocyst densities in infected mosquitoes.
Statistical analyses were done using SPSS for Windows (version 
12.0; SPSS) and Stata (version 8.0; Stata Corporation). Propor­
tions were compared using the x 2 test and the McNemar test for 
matched-pair data was used to analyse the directional selection of 
mutations from day 0 to day 14. Normally distributed continuous 
variables were compared using the Student’s t test. Variables that 
were not normally distributed were compared using the Wilcoxon 
rank-sum test. The influence of the number of mutations in 
infections at enrolment on the proportion of infected mosquitoes at 
day 14 was tested using logistic regression models with Generalized
Estimating Equations (GEE); the influence of the number of 
mutations in infections at enrolment on oocyst densities in 
mosquitoes was determined using negative binomial regression. 
Estimates were adjusted for observations from the same individual. 
Regression coefficients (b) were calculated with standard errors (se).
Results
Prevalence of mutant dhfr genotypes, enrolment 
parasitemia and gametocyte carriage
The relation between mutations in dhfr, enrolment parasitemia, 
parasite clearance and post-treatment gametocyte carriage was 
determined in baseline samples from 134 individuals treated with SP 
or SP+AQ (non-ACT) and 57 individuals treated with SP+AS 
(ACT). None of the infections consisted solely of wild-type parasites 
at the dhfr locus: all 191samples had the 108N mutation and at least 
one additional mutation in c51 (85.9%, 164/191) or c59 (79.6%, 
152/191). (The I164L substitution at codon 164 was not evaluated in 
these preliminary experiments.) Based on these three codons, 33.5% 
(64/191) of the parasite isolates harboured double mutant dhfr loci; 
the remaining 66.5% (127/191) harboured infections with mutations 
at all three codons. In  the absence of wild-type infections as reference 
category, these two groups were compared.
Enrolment asexual parasite density was not related to the number 
of dhfr mutations (table 1). Asexual parasites were still detectable on 
day 3 after treatment in 14.5% (19/131) of the individuals treated 
with non-ACTs and in 1.8% (1/56) of those treated with ACTs 
(p<0.001), without a relation with the number of parasite 
mutations. Gametocyte prevalence at enrolment was 26.5% (50/ 
189) by microscopy and 91.4% (118/129) by Pfs25 QT-NASBA, 
and was not associated with the number of dhfr mutations. 
Transmission potential during follow-up was quantified as the area 
under the curve (AUC) of Pfs25 QT-NASBA gametocyte density 
versus time for non-ACT and A CT treated children (table 1). The 
AUC was significantly lower for ACT compared to non-ACT 
treated children (p<0.001). Within the group of non-ACT treated 
individuals, AUC was positively associated with the presence of 
asexual parasites on day three after treatment (i.e. a longer parasite 
clearance time), p = 0.046. There was no relation between AUC 
and the presence of three mutations in infections for either non­
A CT or ACT treated individuals.
The lack of wild-type dhfr loci among this preliminary baseline 
analysis at three codons suggested that it would not be possible to 
find associations between parasite genotype and treatment 
outcomes of interest such as gametocyte carriage and mosquito 
infectivity using this approach. Therefore, in subsequent analyses 
we tested for the (rare) substitution of Leucine for isoleucine at 
codon 164 of dhfr, and performed a full analysis of the dhps gene at 
codons 436, 437, 540, 581 and 613. Significant associations with 
treatm ent outcome and parasite transmissibility have been shown 
for mutations at codons 437 [25] and 540 [19].
Prevalence and post-treatment selection of mutant 
parasite genotypes in individuals included in 
transmission experiments
Seventy-five individuals donated blood for random mem brane­
feeding experiments and subsequent QT-NASBA analyses [27]. 
Fifty-eight of these individuals contributed to parasite DNA 
analyses of SNPs in dhfr and dhps at both day 0 and day 14 
(figure 1). In this group, dhfr genotyping for day 0 samples was 
successful in 100% (58/58) for all codons, except for c59 (57/58). 
For the day 14 samples, approximately half of whom were 
parasite-negative by microscopy, dhfr genotyping was successful in 
71% (41/58) for c51 and c59, in 70% (40/58) for c108 and c164.
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Table 1. Enrolment characteristics and gametocyte carriage 
in relation to mutations in the dhfr gene.
Double mutation* Three mutations* p-value
Median asexual parasite density at enrolment (IQR)
Non-ACT 10,880 (2,280-31,820) 14,320 (5,020-30,360) 0.27
ACT 12,080 (4,560-39,200) 13,560 (4,020-32,760) 0.99
Proportion of parasitemic children at day 3, %  (n/N)
Non-ACT 10.0 (4/40) 16.5 (15/91) 0.33
ACT 4.5 (1/22) 0.0 (0/34) 0.39
Adequate clinical response, %  (n/N)
Non-ACT 58.3 (21/36) 63.6 (49/77) 0.59
ACT 71.4 (15/21) 86.7 (26/30) 0.18
Microscopic gametocyte prevalence at enrolment, %  (n/N)
Non-ACT 22.5 (9/40) 26.1 (24/92) 0.66
ACT 21.7 (5/23) 35.5 (12/34) 0.27
QT-NASBA gametocyte prevalence at enrolment, %  (n/N)
Non-ACT 88.9 (16/18) 91.5 (65/71) 0.66
ACT 87.5 (14/16) 95.8 (23/24) 0.55
Median AUC of QT-NASBA gametocyte density¥/mL versus time", (IQR)
Non-ACT 4.23 (0.39-20.14) 6.13 (1.56-15.88) 0.54
ACT 0.17 (0.02-2.82) 0.29 (0.17-82) 0.35
AUC = area under the curve; GM = geometric mean; IQR = interquartile range; 
Non-ACT = treatment with sulphadoxine-pyrimethamine (SP) alone or in 
combination with amodiaquine; ACT = treatment with SP and artesunate 
(3 days).
¥Gametocyte densities were measured by Pfs25 QT-NASBA.
*Mutations were determined at enrolment: double mutation = mutations in 
c108+c59 or c108+c51; three mutations = mutations in c51+c59+c108;
"the period from enrolment until time of feeding (day 14) was considered for 
determining the AUC. 
doi:10.1371/journal.pone.0004364.t001
Dhps genotyping for day 0 samples was successful in 98% (57/58) 
for all codons and for day 14 samples in 47% (27/58) for c436 and 
c437 and in 52% (30/58) for c540, c581 and c613. The 164L 
mutation was found in four infections, in one case as the majority 
(but mixed) genotype and in the other three cases as a mixed 
infection. The presence of the 164L mutation was verified by 
PCR-RFLP for all four samples.
DNA from 20 individuals in the SP+A Q  treatm ent arm was 
available for Pfcrt genotyping. All 20 day 0 samples were 
successfully amplified, while only four of the 20 day 14 samples 
were amplified even after repeating the procedure. Nineteen of the 
twenty day 0 isolates harboured the m utant Pfcrt CVIET 
haplotype, and one individual harboured the CVM NK haplotype. 
Two of the four day 14 samples carried the CVIET haplotype and 
the other two the CVM NK haplotype. The SVM NT haplotype 
was not found. The remainder of the analyses will focus on dhfr 
and dhps mutations.
Fifteen of the 57 individuals (26.3%) included in the m em brane­
feeding experiments had an infection with two mutations in the 
dhfr gene at enrolment. The remaining 42 individuals (73.7%) had 
infections with three (n = 1), four (n = 2) or five (n = 39) mutations 
in the dhfr and dhps genes. Against the background of this high 
prevalence prior to treatment, mutations in c59 and c540 were 
more common in samples on day 14 after non-ACT treatment; 
although this was not statistically significant for either mutation 
(figure 1, McNemar test p = 0.375 and p = 1.00, respectively). The 
proportion of infections with $  three mutations did not increase
significantly on day 14 after non-ACT treatm ent (McNemar test 
p = 0.687) or after ACT treatm ent (McNemar test p = 0.250).
Mutant genotypes and malaria transmission
The median gametocyte density on day 14 after treatm ent was 
similar for both children harbouring infections with two mutations 
in the dhfr and dhps genes and for children with $  three mutations 
in these genes. We found no indication that infections with $  three 
mutations at enrolment were more transmissible (on day 14 after 
treatment) than infections presenting at day 0 with fewer 
mutations. The proportion of children infecting at least one 
mosquito and infected mosquitoes was similar for both groups 
(table 2). Infected mosquitoes (94/1710) harboured 1-13 oocysts. 
We observed no statistically significant association between the 
presence of $  three mutations and oocyst counts in mosquitoes for 
non-ACT treated individuals (b = 0.25, se(b) = 0.54, p = 0.64) or 
A CT treated individuals (b = 0.16, se(b) = 0.73, p = 0.82).
The comparison between A CT and non-ACT treated individuals 
was previously reported in detail for the entire dataset [27]. There, a 
significantly lower proportion of infected mosquitoes following ACT 
treatment was observed [27]. The current analyses show that this 
observed reduction in transmission potential is evident both for 
infections with two mutations in the dhfr and dhps genes and for those 
with $  three mutations (table 2). In the current selection of samples, 
ACT reduced the median gametocyte density on day of feeding 
(p<0.001), the proportion of infected mosquitoes (b = —0.86, 
se(b) = 0.46, p = 0.06) and the mean oocyst burden (b = —0.89, 
se(b) = 0.51, p = 0.08) compared to non-ACT treatment. However, 
we found no evidence this was linked to carriage of mutations in the 
dhfr and dhps genes, which was high in all treatment groups.
Discussion
In this study, we observed a high prevalence of mutations in the 
dhfr and dhps genes of P. falciparum in an area in western Kenya. None 
of the infections harboured fewer than two mutations and the 164L 
mutation, which is rare in East Africa [16-19,40], was found in four 
infections. Against this background of high prevalence rates of 
mutations in the dhfr and dhps genes, and the absence of wild-type 
infections to use as comparators, we found no association between 
the number of mutations in the dhfr or dhps genes and (sub)micro- 
scopic gametocytemia or the infectiousness to mosquitoes.
High prevalences of dhfr and dhps mutations are not uncommon in 
East Africa [15,41,42]. In our study population, where we previously 
reported that SP monotherapy gave an adequate clinical response in 
only 44% of the cases [27], we found that approximately 70% of the 
infections prior to treatment harboured dhfr loci with three 
mutations. The finding of the 164L mutation is an additional 
indication for the high level of SP resistance. There are only a few 
other studies that reported the 164L mutation in Africa [15-19]. In 
our study, three of the four samples with the 164L mutation also 
contained $  three mutations in other codons, indicating that the 
next step in the sequence of mutations has been reached. This 
suggests that SP treatment efficacy could deteriorate further 
[9,13,14] if drug pressure continues and strongly supports the policy 
change to AL as first-line antimalarial treatment [1]. Hamel and 
others found that the 164L mutation in a high endemic area was not 
associated with high-level SP resistance or poor outcome among 
adults [40], but the involvement of this mutation in treatment 
outcomes for children has yet to be elucidated.
We observed a high prevalence of the Pfcrt m utant CVIET 
haplotype, as previously observed in Kenya [43] and Tanzania 
[42,44]. A persisting high prevalence of Pfcrt mutant parasites after 
abandoning C Q as  first line treatm ent was also reported in central
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Figure 1. Prevalence of mutant genotypes for dhfr and dhps genes prior to treatment and on day  14 after non-ACT or ACT  
treatment in sam ples included in the membrane-feeding assays. Non-ACT = sulphadoxine-pyrimethamine (SP) alone or in combination with 
amodiaquine; ACT = SP in combination with artesunate; $  three mutations = mutations in c51+c59+c108 and possible additional mutations The 
number of observations on day 0: all mutations (n = 57-58) (see text); on day 14 after non-ACT treatment: c51, c59, c108, c164 (n = 33); c436, c437 
(n = 23); c540, c581, c613 (n = 25); $  three mutations (n = 33); on day 14 after ACT treatment: c51, c59 (n = 8); c108, c164 (n = 7); c436, c437 (n = 4); 
c540, c581, c613 (n = 5); $  three mutations (n = 7). 
doi:10.1371/journal.pone.0004364.g001
Kenya [45], although a reduction in its prevalence was observed in 
other countries [46,47]. The Pfcrt gene is also associated with A Q  
resistance [44,48]. A Q  was widely used in the study area in 
government facilities in the period the study was conducted and 
continues to be a popular choice for home treatm ent with shop- 
bought drugs. In the year prior to the current study, we observed 
that 30.6% (26/85) of children attending the clinic with 
uncomplicated malaria had metabolites of 4-aminoquinolines in 
their urine (Bousema, unpublished observations). Although the 
used dipstick method could not differentiate between A Q an d  CQ, 
it is likely that the high frequency of the CVIET haplotype is 
currently being maintained by the use of AQ, rather than CQ.
Previous studies have found a relation between mutations in the 
dhfr and dhps genes and treatm ent outcome, but only when a 
substantial proportion of the parasite population harboured wild­
type alleles [8,21]. This was not the case in our population where 
we observed no additional risk of treatm ent failure for infections 
with $  three mutations in the dhfr gene compared to double 
mutations. In line with this, the number of parasite mutations was 
not related with the proportion of individuals in whom asexual
parasites were still detectable on day 3, an indicator of parasite 
clearance time (PCT).
This is the first report that describes the relationship between 
submicroscopic gametocytemia and the presence of mutant 
genotypes. Mutations in the dhfr gene have previously been 
related to an increased microscopic gametocyte prevalence after 
SP treatm ent [20-23]. This observation may be partly explained 
by a longer PC T for m utant parasites; this prolonged survival time 
under drug pressure allows parasites to invest in transmission 
stages [20]. In an earlier study, we have shown that peaks in 
microscopic gametocyte prevalence after treatm ent are likely to be 
the result of an increase in the density of gametocytes that were 
already present before treatm ent at submicroscopic concentrations 
[49]. We therefore hypothesized that post-treatment gametocyte 
density (measured by QT-NASBA) would be increased for 
infections with mutations in the dhfr and dhps genes. However, 
the complete absence of wild-type infections in our study 
population prevented this comparison being made. W hen using 
infections with a double mutation in the dhfr gene as reference 
group, we did not observe any association between the presence of
PLoS ONE | www.plosone.org 5 February 2009 | Volume 4 | Issue 2 | e4364
SP Resistance and Transmission
Table 2. Post-treatment malaria transmission in relation to 
mutations in the dhfr and dhps genes.
Double mutation* a  three mutations* p-value
Median gametocyte density/mL ¥ on day of feeding, (IQR)
Non-ACT 10.40 (3.83-30.33) 4.96 (0.51-22.47) 0.27
ACT 0.84 (0.03-1.94) 0.17 (0.04-1.01) 0.66
Proportion of children infecting at least one mosquito, %  (n/N)
Non-ACT 77.8 (7/9) 73.5 (25/34) 1.00
ACT 50.0 (3/6) 62.5 (5/8) 1.00
Proportion of infected mosquitoes, %  (n/N)1
Non-ACT 7.0 (19/270) 6.0 (61/1020) 0.79
ACT 3.2 (6/180) 3.3 (8/240) 0.65
IQR = interquartile range; Non-ACT = treatment with sulphadoxine- 
pyrimethamine (SP) alone or in combination with amodiaquine;
ACT = treatment with SP and artesunate (3 days).
¥Gametocyte densities were measured by Pfs25 QT-NASBA.
*Mutations were determined at enrolment: double mutation = mutations in 
c108+c59 or c108+c51; $  three mutations = mutations in c51+c59+c108 and 
possible additional mutations;
Estimates were adjusted for correlation between observations from the same 
individual.
doi:10.1371/journal.pone.0004364.t002
additional mutations in the dhfr or dhps genes and the prevalence or 
density of submicroscopic gametocytes. The transmission poten­
tial, quantified as the area under the curve of Pfs25 QT-NASBA 
gametocyte density versus time, was not associated with additional 
mutations compared to the reference group. In line with this, we 
also observed no increased malaria transmission measured by 
membrane feeding experiments on day 14 after treatm ent in 
relation to additional dhfr/dhps mutations. This contrasts with 
studies from the Gambia where a substantial proportion of 
parasites carried wild-type Pfcrt alleles. Here, increased transmis­
sion of C Q  resistant parasite strains was observed after 
examination of a similar number of transmission experiments 
and (infected) mosquitoes [23-25]. A recent study from Colombia 
also observed that infections with two dhfr mutations (in c108 and 
c51) had a 10-fold higher probability of infecting mosquitoes than 
infection with wild-type parasites [26].
Limitations
In our study area of moderate transmission intensity, many of 
the study participants will have harboured multiple clone 
infections. We have presented estimates of mutation prevalence,
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